1. Home
  2. MAN vs MESO Comparison

MAN vs MESO Comparison

Compare MAN & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ManpowerGroup

MAN

ManpowerGroup

N/A

Current Price

$61.90

Market Cap

2.4B

ML Signal

N/A

Logo Mesoblast Limited

MESO

Mesoblast Limited

N/A

Current Price

$17.30

Market Cap

2.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MAN
MESO
Founded
1948
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.1B
IPO Year
1994
2005

Fundamental Metrics

Financial Performance
Metric
MAN
MESO
Price
$61.90
$17.30
Analyst Decision
Hold
Strong Buy
Analyst Count
6
1
Target Price
$35.67
N/A
AVG Volume (30 Days)
771.1K
179.9K
Earning Date
04-16-2026
02-26-2026
Dividend Yield
4.69%
N/A
EPS Growth
N/A
N/A
EPS
1.19
N/A
Revenue
$17,957,100,000.00
N/A
Revenue This Year
$5.12
$629.74
Revenue Next Year
$3.42
$30.65
P/E Ratio
$51.24
N/A
Revenue Growth
0.58
N/A
52 Week Low
$25.15
$13.05
52 Week High
$63.88
$21.50

Technical Indicators

Market Signals
Indicator
MAN
MESO
Relative Strength Index (RSI) 63.19 53.65
Support Level $25.93 $16.56
Resistance Level N/A $17.33
Average True Range (ATR) 2.12 0.47
MACD -0.57 -0.04
Stochastic Oscillator 60.86 32.80

Price Performance

Historical Comparison
MAN
MESO

About MAN ManpowerGroup

ManpowerGroup Inc provides workforce solutions and services, including recruitment and assessment, upskilling, reskilling, training and development, career management, outsourcing, and workforce consulting. The company leverages its trusted brands, industry knowledge, and AI-enabled assessments and offers an extensive portfolio of training and leadership development solutions. Its reportable segments are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others, with Staffing and Interim generating the majority of revenue. It operates in the Americas, Southern Europe, Northern Europe, and APME. The company derives the maximum geographical revenue from the Southern European region.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: